Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients

Alessandra Mazzola; Eve Todesco; Sarah Drouin; Fanny Hazan; Stéphane Marot; Dominique Thabut; Shaida Varnous; Cathia Soulié; Benoît Barrou; Anne-Geneviève Marcelin; Filomena Conti

doi:10.1093/cid/ciab580

Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients

Clin Infect Dis. 2022 Mar 23;74(6):1093-1096. doi: 10.1093/cid/ciab580.

Affiliations

¹ Sorbonne Université, Unité Médicale de Transplantation Hépatique, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
² Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de Virologie, Paris, France.
³ Sorbonne Université, Service Médico-chirugical de Transplantation rénale, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
⁴ Sorbonne Université, Chirurgie Cardiaque et Thoracique, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
⁵ Sorbonne Université, Service d'Hépato-gastroentérologie, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.

Abstract

A low anti-spike antibody response of 28.6% was observed 28 days after BNT162b2 vaccine second dose among 133 solid organ transplant recipients without previous coronavirus disease 2019 (COVID-19). No serious adverse events were recorded. Four severe COVID-19 cases were reported between or after the 2 doses. Our data suggest to change the vaccine strategy.

Keywords: COVID-19 disease; SARS-CoV-2 vaccination; SOT recipients; anti-spike antibodies; humoral response.

MeSH terms

Antibodies, Viral
Antibody Formation
BNT162 Vaccine
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
SARS-CoV-2*
Transplant Recipients

Substances

Antibodies, Viral
COVID-19 Vaccines
BNT162 Vaccine